BLAINJECTIONINJECTABLEPriority Review
Approved
Oct 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
9
Mechanism of Action
Claudin 18.2-directed Antibody Interactions
Pharmacologic Class:
Claudin 18.2-directed Cytolytic Antibody
Clinical Trials (5)
A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer
Started Sep 2025
12 enrolled
Metastatic Pancreatic Adenocarcinoma
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Started May 2025
500 enrolled
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
Started Apr 2025
377 enrolled
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
Started Oct 2019
12 enrolled
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
Started Mar 2019
393 enrolled
Pancreatic CancerMetastatic Pancreatic CancerMetastatic Pancreatic Adenocarcinoma